Final answer:
The 'One Pill, Once a Day' regimen potentially being referred to is a combination of dolutegravir (an INSTI) and lamivudine (an NRTI), known as Dovato. This is for selected HIV patients without HBV coinfection and certain viral load restrictions.
Step-by-step explanation:
The question you've asked pertains to a specialized ART therapy regimen for the treatment of HIV. In this context, the regimen you're asking about involves two types of antiretroviral drugs: an integrase strand transfer inhibitor (INSTI) and a nucleoside reverse transcriptase inhibitor (NRTI). However, most standard ART regimens involve at least three antiretroviral drugs from at least two different classes to effectively control HIV and prevent the development of drug resistance.
For cases with specific restrictions regarding viral load and coinfection with hepatitis B virus (HBV), the 'One Pill, Once a Day' regimen you mentioned could potentially be dolutegravir used in combination with lamivudine (brand name Dovato), which is a treatment option that might be recommended for some patients. However, it's important to note that this regimen is only suitable for individuals without HBV infection and with a baseline viral load which typically should be under 500,000 copies/mL. Due to the specific criteria and potential exceptions, such treatment decisions are made on an individual basis and must involve careful consideration by a healthcare professional.